3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
5
Adenocarcinoma of Lung
5
Lymphoma, Large-Cell, Anaplastic
2
Hematologic Neoplasms
2
Granuloma, Plasma Cell
2
Rhabdomyosarcoma
1
Noonan Syndrome 6
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Lymphoma, B-Cell
1
Glioblastoma
1
Brain Neoplasms
1
ALK-positive Non-small Cell Lung Cancer
1
ALK-positive NSCLC
1
Interventions
Rituximab
40
Cyclophosphamide
29
Etoposide
15
Doxorubicin
14
Vincristine
13
Prednisone
13
ibrutinib
10
fludarabine
10
fludarabine phosphate
8
Cytarabine
8
Mycophenolic Acid
7
Bortezomib
7
Lenalidomide
6
Carmustine
6
pembrolizumab
5
Peripheral Blood Stem Cell Transplantation
5
Melphalan
5
Inotuzumab Ozogamicin
5
Whole-Body Irradiation
4
Tacrolimus
4
Carboplatin
4
CT-P10
4
Brentuximab Vedotin
4
Antilymphocyte Serum
4
tositumomab I-131
3
tocilizumab
3
tazemetostat
3
obinutuzumab
3
idelalisib
3
etoposide phosphate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, B-Cell
×
ceritinib
×
Clear all
NCT02186821
2021-04-08
SIGNATURE
Novartis
Phase 2
Terminated
47 enrolled
13 charts